UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer

World journal of urology, 2017-03, Vol.35 (3), p.367-378

2017

Volltextzugriff (PDF)

Phase III double-blind study evaluating lens opacifications (LO) in patients with nonmetastatic prostate cancer (PCa) receiving denosumab (Dmab) for bone loss due to androgen deprivation therapy (ADT)

Annals of oncology, 2018-10, Vol.29, p.viii295-viii296

2018

Volltextzugriff (PDF)

Folate hydrolase‐1 (FOLH1) is a novel target for antibody‐based brachytherapy in Merkel cell carcinoma

Skin health and disease, 2021-03, Vol.1 (1), p.n/a

2021

Volltextzugriff (PDF)

TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes

Annals of oncology, 2024-04, Vol.35 (4), p.392-401

2024

Volltextzugriff (PDF)

Cytotoxic chemotherapy in the treatment of advanced renal cell carcinoma in the era of targeted therapy

Critical reviews in oncology/hematology, 2015-12, Vol.96 (3), p.518-526

2015

Volltextzugriff (PDF)

Clinico-genomic profiling and outcome prediction of neuroendocrine prostate cancer (NEPC)

Annals of oncology, 2018-10, Vol.29, p.viii293-viii294

2018

Volltextzugriff (PDF)

Phase I dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)

Annals of oncology, 2018-10, Vol.29, p.viii274-viii274

2018

Volltextzugriff (PDF)

Boning up on prognostic factors in advanced renal cell carcinoma

Annals of oncology, 2011-04, Vol.22 (4), p.751-753

Tagawa, S.T.

2011

Volltextzugriff (PDF)

Synthetic DNA immunotherapy in biochemically relapsed prostate cancer

Annals of oncology, 2018-10, Vol.29, p.viii290-viii290

2018

Volltextzugriff (PDF)

845PPhase III double-blind study evaluating lens opacifications (LO) in patients with nonmetastatic prostate cancer (PCa) receiving denosumab (Dmab) for bone loss due to androgen deprivation therapy (ADT)

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

839PClinico-genomic profiling and outcome prediction of neuroendocrine prostate cancer (NEPC)

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

888PCirculating tumour cell (CTC) genomic landscape in neuroendocrine prostate cancer (NEPC) by single cell copy number analysis

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

849PDPreliminary results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

895TiPA phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

LBA55Initial results from TROPHY-U-01: A phase II open-label study of sacituzumab govitecan in patients (Pts) with metastatic urothelial cancer (mUC) after failure of platinum-based regimens (PLT) or immunotherapy

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Anti-prostate-specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 immunotherapy for prostate cancer

Annals of oncology, 2016-10, Vol.27, p.vi265-vi265

2016

Volltextzugriff (PDF)

A phase 2 study of the aurora kinase A inhibitor alisertib for patients with neuroendocrine prostate cancer (NEPC)

Annals of oncology, 2016-10, Vol.27, p.vi565-vi565

2016

Volltextzugriff (PDF)

Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody

Lab on a chip, 2010-01, Vol.10 (1), p.27-29

2010

Volltextzugriff (PDF)

PO-43 - Differential coagulation factor expression in neuroendocrine prostate cancer (PC), metastatic castrate-resistant PC, and localized prostatic adenocarcinoma

Thrombosis research, 2016-04, Vol.140, p.S192-S192

2016

Volltextzugriff (PDF)

799PDPhase I dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

845PDCDK12-altered prostate cancer: Clinical features and therapeutic outcomes to standard systemic therapies, PARP inhibitors, and PD1 inhibitors

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

830PSynthetic DNA immunotherapy in biochemically relapsed prostate cancer

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

OC-14 - Baseline D-dimer levels are predictive of recurrent venous thromboembolism (VTE) at 6 months in cancer patients with VTE treated with tinzaparin

Thrombosis research, 2016-04, Vol.140, p.S174-S174

2016

Volltextzugriff (PDF)

Targeted Therapy for Locally Advanced or Metastatic Urothelial Cancer (mUC): Therapeutic Potential of Sacituzumab Govitecan

OncoTargets and therapy, 2022-01, Vol.15, p.1531-1542

2022

Volltextzugriff (PDF)

Microtubule inhibitor-based antibody-drug conjugates for cancer therapy

OncoTargets and therapy, 2014-01, Vol.7 (default), p.2227-2236

2014

Volltextzugriff (PDF)

1 – 25 von 10.222

Suche als RSS-Feed

Aktive Filter

ThemaAdult

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(6.325)
Mit Volltextzugriff
(7.804)

Publikationsform

6 weitere anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(4.519)
IngentaConnect Journals
(2.788)
MEDLINE
(2.326)
Journals@Ovid Complete
(1.506)
Publisher website
(1.439)
Elsevier ScienceDirect Journals Complete
(1.387)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(1.021)
IngentaConnect Journals
(898)
Wiley Online Library Journals Frontfile Complete
(749)
SpringerLink
(528)
IEEE
(509)
Wiley Online Library Full Collection 2018
(456)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(367)
Oxford Journals Online Current
(226)
Springer Nature - Connect here FIRST to enable access
(203)
Taylor & Francis Journals
(161)
Taylor & Francis Online
(145)
Taylor & Francis Current Content Access
(137)
Nexis Uni
(113)
Scitation (American Institute of Physics)
(103)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer

Phase III double-blind study evaluating lens opacifications (LO) in patients with nonmetastatic prostate cancer (PCa) receiving denosumab (Dmab) for bone loss due to androgen deprivation therapy (ADT)

Folate hydrolase‐1 (FOLH1) is a novel target for antibody‐based brachytherapy in Merkel cell carcinoma

TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes

Cytotoxic chemotherapy in the treatment of advanced renal cell carcinoma in the era of targeted therapy

Clinico-genomic profiling and outcome prediction of neuroendocrine prostate cancer (NEPC)

Phase I dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)

Boning up on prognostic factors in advanced renal cell carcinoma

Synthetic DNA immunotherapy in biochemically relapsed prostate cancer

845PPhase III double-blind study evaluating lens opacifications (LO) in patients with nonmetastatic prostate cancer (PCa) receiving denosumab (Dmab) for bone loss due to androgen deprivation therapy (ADT)

839PClinico-genomic profiling and outcome prediction of neuroendocrine prostate cancer (NEPC)

888PCirculating tumour cell (CTC) genomic landscape in neuroendocrine prostate cancer (NEPC) by single cell copy number analysis

849PDPreliminary results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)

895TiPA phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

LBA55Initial results from TROPHY-U-01: A phase II open-label study of sacituzumab govitecan in patients (Pts) with metastatic urothelial cancer (mUC) after failure of platinum-based regimens (PLT) or immunotherapy

Anti-prostate-specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 immunotherapy for prostate cancer

A phase 2 study of the aurora kinase A inhibitor alisertib for patients with neuroendocrine prostate cancer (NEPC)

Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody

PO-43 - Differential coagulation factor expression in neuroendocrine prostate cancer (PC), metastatic castrate-resistant PC, and localized prostatic adenocarcinoma

799PDPhase I dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)

845PDCDK12-altered prostate cancer: Clinical features and therapeutic outcomes to standard systemic therapies, PARP inhibitors, and PD1 inhibitors

830PSynthetic DNA immunotherapy in biochemically relapsed prostate cancer

OC-14 - Baseline D-dimer levels are predictive of recurrent venous thromboembolism (VTE) at 6 months in cancer patients with VTE treated with tinzaparin

Targeted Therapy for Locally Advanced or Metastatic Urothelial Cancer (mUC): Therapeutic Potential of Sacituzumab Govitecan

Microtubule inhibitor-based antibody-drug conjugates for cancer therapy

Aktive Filter

Suchergebnisse filtern